Adding tafasitamab to treatment with lenalidomide and rituximab improved outcomes in patients with relapsed or refractory follicular lymphoma.

Antibody–drug conjugates (ADCs) are a broad class of molecules comprising of a potent cytotoxic agent conjugated with a monoclonal antibody using a chemically stable linker. By selecting a ...

Late-onset neutropenia (LON) is emerging as a common adverse effect to rituximab therapy owing to widespread use of this drug in the treatment of B-cell lymphomas and autoimmune diseases.